Head to Head Comparison: Cardiol Therapeutics (NASDAQ:CRDL) versus Integrated BioPharma (OTCMKTS:INBP)

Cardiol Therapeutics (NASDAQ:CRDL) and Integrated BioPharma (OTCMKTS:INBP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, dividends, profitability, earnings and valuation.

Volatility and Risk

Cardiol Therapeutics has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500. Comparatively, Integrated BioPharma has a beta of 0.41, suggesting that its share price is 59% less volatile than the S&P 500.

Earnings & Valuation

This table compares Cardiol Therapeutics and Integrated BioPharma”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiol Therapeutics	N/A	N/A	-$24.20 million	($0.28)	-4.77
Integrated BioPharma	$54.35 million	0.14	$810,000.00	($0.02)	-12.00

Integrated BioPharma has higher revenue and earnings than Cardiol Therapeutics. Integrated BioPharma is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Cardiol Therapeutics and Integrated BioPharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardiol Therapeutics	N/A	-239.10%	-165.77%
Integrated BioPharma	-0.40%	-1.02%	-0.83%

Analyst Ratings

This is a summary of recent ratings and target prices for Cardiol Therapeutics and Integrated BioPharma, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiol Therapeutics	1	0	2	0	2.33
Integrated BioPharma	0	0	0	0	0.00

Cardiol Therapeutics presently has a consensus price target of $8.50, indicating a potential upside of 536.70%. Given Cardiol Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Cardiol Therapeutics is more favorable than Integrated BioPharma.

Insider and Institutional Ownership

12.5% of Cardiol Therapeutics shares are owned by institutional investors. Comparatively, 25.3% of Integrated BioPharma shares are owned by institutional investors. 5.3% of Cardiol Therapeutics shares are owned by company insiders. Comparatively, 67.4% of Integrated BioPharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Integrated BioPharma beats Cardiol Therapeutics on 7 of the 13 factors compared between the two stocks.

About Cardiol Therapeutics

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

About Integrated BioPharma

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.